Chondroitin sulfate proteoglycan 4 (CSPG4/NG2) was used as a targeting agent as it is highly expressed in triple-negative breast cancer (TNBC) and malignant melanoma. Here, CSPG4 is linked to triple-negative breast carcinoma.